<DOC>
	<DOCNO>NCT03042312</DOCNO>
	<brief_summary>Studies assess safety efficacy 177Lu-PSMA-617 patient metastatic castration resistant prostate cancer .</brief_summary>
	<brief_title>Lutetium-177 ( Lu177 ) Prostate-Specific Antigen ( PSMA ) -Directed EndoRadiotherapy</brief_title>
	<detailed_description>Primary goal study evaluation safety efficacy 177Lu-PSMA-617 . Safety 177Lu-PSMA-617 ( Radioligand Therapy ) RLT assess analysis toxicity . Descriptive statistic ( number percentage ) report separately Adverse Events ( AE ) total Serious Adverse Events ( SAE ) . These descriptive statistic present whole treatment well separate cycle . In addition , relationship AE study drug ( relate , relate ) report . Both result laboratory test , physical examination patient survey include . Efficacy 177Lu-PSMA-617 report use descriptive statistic mean number percentage patient ≥50 % decline 12-weeks baseline .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Prostate cancer proven histopathology 2 . Unresectable metastasis 3 . Progressive disease , docetaxel/cabazitaxel naive docetaxel/cabazitaxel treat . 4 . Castration resistant disease confirm testosterone level ≤50 ng/ml prior androgen deprivation therapy ( ADT ) 5 . Positive 68GaPSMA11 PET/CT ( positron emission compute tomography ) diagnostic 177LuPSMA617 scintigraphy 6 . ECOG 02 7 . Sufficient bone marrow capacity define WBC ( white blood cell ) ≥2.000/μl , PLT ( platelet ) count ≥75.000/μl , Hb≥8.9 g/dl ANC≥1000 mm3 . 8 . Signing Informed Consent Form 1 . Less 6 week since last myelosuppressive therapy ( include Docetaxel , Cabazitaxel , 223Ra , 153Sm ) radionuclide therapy 2 . Glomerular Filtration Rate ( GFR ) &lt; 40 ml/min 3 . Grade 3 toxicity serum creatinine use CTCAE v. 4.0 4 . AST ( aspartate aminotransferase ) ALT ( alanine transferase ) &gt; 5xULN 5 . Urinary tract obstruction mark hydronephrosis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>